-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Freeline Therapeutics Holdings plc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and change rate from 2018 to Q1 2023.
- Freeline Therapeutics Holdings plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending March 31, 2023 was $1.33M.
- Freeline Therapeutics Holdings plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$88.6M, a 36.7% increase from 2021.
- Freeline Therapeutics Holdings plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$140M, a 45.6% decline from 2020.
- Freeline Therapeutics Holdings plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was -$96.2M, a 78.9% decline from 2019.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)